Organon (OGN) Prices $1B Notes Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
May 7, 2024 8:20 PM EDTJERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) (Organon), a global healthcare company with a focus on womens health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the Co-Issuer and, together with Organon, the Companies), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the Secured Notes) and $500 million of 7.875% senior unsecured notes due 2034 (the Unsecured Notes and, together with the Secured Notes the Notes). Each series of notes will be guaranteed by each of the entities that guarantees the Companies existing... More



